| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000266 | Mitochondrial fission | Affects phenotype | PMID:36115506 |
| GO:0001655 | Urogenital system development | Affects phenotype | PMID:32360330 |
| GO:0001774 | Microglial cell activation | Increases phenotype | PMID:31894355 |
| GO:0001958 | Endochondral ossification | Decreases phenotype | PMID:33367866 |
| GO:0005739 | Mitochondrion | Increases phenotype | PMID:38518089 |
| GO:0006497 | Protein lipidation | Increases phenotype | PMID:36375964 |
| GO:0006754 | Atp biosynthetic process | Affects phenotype | PMID:28641197 |
| GO:0006914 | Autophagy | Increases phenotype | PMID:28025121 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:28025121; PMID:28641197; PMID:31894355; PMID:36375964 |
| GO:0007005 | Mitochondrion organization | Affects phenotype | PMID:35135005 |
| GO:0007040 | Lysosome organization | Increases phenotype | PMID:35135005 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:27816613 |
| GO:0008219 | Cell death | Increases phenotype | PMID:26179874; PMID:28181390 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:28181390 |
| GO:0008284 | Positive regulation of cell population proliferation | Increases phenotype | PMID:26979758 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:28959647; PMID:29783866; PMID:30842366 |
| GO:0008923 | Lysine decarboxylase activity | Decreases phenotype | PMID:25264276 |
| GO:0009060 | Aerobic respiration | Increases phenotype | PMID:30966736 |
| GO:0010001 | Glial cell differentiation | Increases phenotype | PMID:28851516 |
| GO:0010918 | Positive regulation of mitochondrial membrane potential | Affects phenotype | PMID:27816613; PMID:38331085 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:28959647 |
| GO:0016477 | Cell migration | Decreases phenotype | PMID:33969458 |
| GO:0030182 | Neuron differentiation | Increases phenotype | PMID:28851516 |
| GO:0030539 | Male genitalia development | Affects phenotype | PMID:33280148 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:26979758 |
| GO:0034976 | Response to endoplasmic reticulum stress | Increases phenotype | PMID:27816613 |
| GO:0040018 | Positive regulation of multicellular organism growth | Increases phenotype | PMID:32360330 |
| GO:0042632 | Cholesterol homeostasis | Decreases phenotype | PMID:30966736 |
| GO:0042701 | Progesterone secretion | Affects phenotype | PMID:36115506 |
| GO:0043005 | Neuron projection | Decreases phenotype | PMID:24717766 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:24717766; PMID:27816613; PMID:30842366; PMID:38331085 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:28025121; PMID:28641197; PMID:36115506 |
| GO:0045851 | Ph reduction | Increases phenotype | PMID:28025121 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Increases phenotype | PMID:28959647; PMID:30842366 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:30966736; PMID:36115506 |
| GO:0048709 | Oligodendrocyte differentiation | Decreases phenotype | PMID:33969458 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:28641197 |
| GO:0051882 | Mitochondrial depolarization | Increases phenotype | PMID:36115506 |
| GO:0051901 | Positive regulation of mitochondrial depolarization | Increases phenotype | PMID:34036598 |
| GO:0052689 | Carboxylic ester hydrolase activity | Decreases phenotype | PMID:32511959 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:28181390 |
| GO:0060612 | Adipose tissue development | Increases phenotype | PMID:36493961 |
| GO:0070328 | Triglyceride homeostasis | Decreases phenotype | PMID:30966736 |
| GO:0070343 | White fat cell proliferation | Increases phenotype | PMID:36493961 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:28025121; PMID:36115506 |
| GO:0140042 | Lipid droplet formation | Affects phenotype | PMID:35135005 |
| GO:1902237 | Positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | Increases phenotype | PMID:38331085 |
| GO:1902476 | Chloride transmembrane transport | Decreases phenotype | PMID:29783866 |
| GO:1903407 | Negative regulation of p-type sodium:potassium-exchanging transporter activity | Increases phenotype | PMID:29783866 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:27816613; PMID:30842366; PMID:35135005; PMID:38603619 |
| GO:2000866 | Positive regulation of estradiol secretion | Increases phenotype | PMID:38603619 |
| GO:2000872 | Positive regulation of progesterone secretion | Increases phenotype | PMID:38603619 |
| GO:2001170 | Negative regulation of atp biosynthetic process | Increases phenotype | PMID:38331085 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.